A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape

Elisabeth Castellanos(Institute of Predictive and Personalized Medicine of Cancer), Bernat Gel(Institute of Predictive and Personalized Medicine of Cancer), Inma Rosas(Institute of Predictive and Personalized Medicine of Cancer), Eva Tornero(Institut Català d'Oncologia), Sheila Santín(Institute of Predictive and Personalized Medicine of Cancer), Raquel Pluvinet(Institute of Predictive and Personalized Medicine of Cancer), Juan Velasco(Institute of Predictive and Personalized Medicine of Cancer), Lauro Sumoy(Institute of Predictive and Personalized Medicine of Cancer), Jesús Del Valle(Institut Català d'Oncologia), Manuel Perucho(Institute of Predictive and Personalized Medicine of Cancer), Ignacio Blanco(Hospital Universitari Germans Trias i Pujol), Matilde Navarro(Institut Català d'Oncologia), Joan Brunet(Institut Català d'Oncologia), Marta Pineda(Institut Català d'Oncologia), Lídia Feliubadaló(Institut Català d'Oncologia), Gabi Capellá(Institut Català d'Oncologia), Conxi Lázaro(Institut Català d'Oncologia), Eduard Serra(Institute of Predictive and Personalized Medicine of Cancer)
Scientific Reports
January 4, 2017
Cited by 56Open Access
Full Text

Abstract

We wanted to implement an NGS strategy to globally analyze hereditary cancer with diagnostic quality while retaining the same degree of understanding and control we had in pre-NGS strategies. To do this, we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes. We improved bait design, tested different NGS platforms and created a clinically driven custom data analysis pipeline. The I2HCP panel was developed using a training set of hereditary colorectal cancer, hereditary breast and ovarian cancer and neurofibromatosis patients and reached an accuracy, analytical sensitivity and specificity greater than 99%, which was maintained in a validation set. I2HCP changed our diagnostic approach, involving clinicians and a genetic diagnostics team from panel design to reporting. The new strategy improved diagnostic sensitivity, solved uncertain clinical diagnoses and identified mutations in new genes. We assessed the genetic variation in the complete set of hereditary cancer genes, revealing a complex variation landscape that coexists with the disease-causing mutation. We developed, validated and implemented a custom NGS-based strategy for hereditary cancer diagnostics that improved our previous workflows. Additionally, the existence of a rich genetic variation in hereditary cancer genes favors the use of this panel to investigate their role in cancer risk.


Related Papers

No related papers found

Powered by citation graph analysis